LS CancerDiag has opened its next funding round in collaboration with Springvest, who provides opportunities to invest in promising unlisted growth companies.
The company aims to raise €5.4M in capital to support the expansion into the United States and introduce DiagMMR® to the largest health care market in the world.
Please visit the Springvest platform, where you can get more information and invest. Investment is done with Tupas digital identification.
Here you can find the information document for the share issue in accordance with Securities Markets Act § 3:2.
Join our cause of improving Lynch syndrome diagnosis and early identification, to intercept and avoid cancers in this large high-risk group.
Minimum amount €2M, Maximum amount €5.4M.
The funding round closed already on March 6th, only 4 days after opening due to high demand. You can still join the cue, should shares become available.